{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T19:59:31Z","timestamp":1786996771388,"version":"build-2736575974"},"reference-count":140,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008533","name":"Case Comprehensive Cancer Center, Case Western Reserve University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008533","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007312","name":"Cleveland Clinic Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["RES514857"],"award-info":[{"award-number":["RES514857"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.semcancer.2020.03.012","type":"journal-article","created":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T11:19:56Z","timestamp":1584789596000},"page":"34-42","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"P2","title":["Coalescing lessons from oxygen sensing, tumor metabolism, and epigenetics to target VHL loss in kidney cancer"],"prefix":"10.1016","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-188X","authenticated-orcid":false,"given":"Abhishek A.","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2020.03.012_bib0005","unstructured":"https:\/\/www.cancer.org\/cancer\/kidney-cancer\/about\/key-statistics.html."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.012_bib0010","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/ng0594-85","article-title":"Mutations of the VHL tumour suppressor gene in renal carcinoma","volume":"7","author":"Gnarra","year":"1994","journal-title":"Nat. Genet."},{"issue":"7456","key":"10.1016\/j.semcancer.2020.03.012_bib0015","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","author":"Cancer Genome Atlas Research, N","year":"2013","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.semcancer.2020.03.012_bib0020","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/ng.2699","article-title":"Integrated molecular analysis of clear-cell renal cell carcinoma","volume":"45","author":"Sato","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2020.03.012_bib0025","series-title":"Uber eine sehr seltene Erkrankung der Netzhaut","first-page":"83","author":"von Hippel","year":"1904"},{"key":"10.1016\/j.semcancer.2020.03.012_bib0030","series-title":"Studien \u00fcber Kleinhirneysten. Bau","first-page":"1","author":"Lindau","year":"1926"},{"key":"10.1016\/j.semcancer.2020.03.012_bib0035","series-title":"Cavern\u00f6se Blutgeschwulst des Gehirnes","first-page":"458","author":"Luschka","year":"1854"},{"key":"10.1016\/j.semcancer.2020.03.012_bib0040","series-title":"Cyst of the Cerebellum With Numerous Small Cysts in the Pancreas and the Kidneys","first-page":"17","author":"Pye-Smith","year":"1885"},{"key":"10.1016\/j.semcancer.2020.03.012_bib0045","series-title":"Intra-Ocular Growths. Two Cases, Brother and Sister, With Peculiar Vascular New Growth, Probably Primary Retinal, Affecting Both Eyes","first-page":"141","author":"Collins","year":"1894"},{"key":"10.1016\/j.semcancer.2020.03.012_bib0050","series-title":"Grosshirnangiom bei Lindauschen (von Hippelscher) Erkrankung","first-page":"23","author":"Rochat","year":"1931"},{"issue":"17","key":"10.1016\/j.semcancer.2020.03.012_bib0055","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJM195104262441704","article-title":"Multiple hypernephromas of the kidney in association with Lindau\u2019s disease","volume":"244","author":"Greene","year":"1951","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.012_bib0060","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/jmg.30.2.104","article-title":"Detailed genetic mapping of the von Hippel-Lindau disease tumour suppressor gene","volume":"30","author":"Richards","year":"1993","journal-title":"J. Med. Genet."},{"issue":"7","key":"10.1016\/j.semcancer.2020.03.012_bib0065","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/hmg\/2.7.879","article-title":"Mapping the Von Hippel-Lindau disease tumour suppressor gene: identification of germline deletions by pulsed field gel electrophoresis","volume":"2","author":"Richards","year":"1993","journal-title":"Hum. Mol. Genet."},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.012_bib0070","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/hmg\/2.3.279","article-title":"Genetic linkage between von Hippel-Lindau disease and three microsatellite polymorphisms refines the localisation of the VHL locus","volume":"2","author":"Crossey","year":"1993","journal-title":"Hum. Mol. Genet."},{"issue":"10","key":"10.1016\/j.semcancer.2020.03.012_bib0075","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/hmg\/2.10.1750","article-title":"TaqI and PstI RFLPs in the von Hippel-Lindau disease gene (VHL)","volume":"2","author":"Richards","year":"1993","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.012_bib0080","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/BF00420947","article-title":"Von Hippel-Lindau disease: identification of deletion mutations by pulsed-field gel electrophoresis","volume":"92","author":"Yao","year":"1993","journal-title":"Hum. Genet."},{"issue":"5112","key":"10.1016\/j.semcancer.2020.03.012_bib0085","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.8493574","article-title":"Identification of the von Hippel-Lindau disease tumor suppressor gene","volume":"260","author":"Latif","year":"1993","journal-title":"Science"},{"issue":"5229","key":"10.1016\/j.semcancer.2020.03.012_bib0090","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.7660130","article-title":"Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C","volume":"269","author":"Kibel","year":"1995","journal-title":"Science"},{"issue":"5229","key":"10.1016\/j.semcancer.2020.03.012_bib0095","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1126\/science.7660122","article-title":"Inhibition of transcription elongation by the VHL tumor suppressor protein","volume":"269","author":"Duan","year":"1995","journal-title":"Science"},{"issue":"20","key":"10.1016\/j.semcancer.2020.03.012_bib0100","doi-asserted-by":"crossref","first-page":"10595","DOI":"10.1073\/pnas.93.20.10595","article-title":"Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein","volume":"93","author":"Iliopoulos","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5413","key":"10.1016\/j.semcancer.2020.03.012_bib0105","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1126\/science.284.5413.455","article-title":"Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function","volume":"284","author":"Stebbins","year":"1999","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.semcancer.2020.03.012_bib0110","first-page":"5447","article-title":"A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation","volume":"12","author":"Semenza","year":"1992","journal-title":"Mol. Cell. Biol."},{"issue":"29","key":"10.1016\/j.semcancer.2020.03.012_bib0115","doi-asserted-by":"crossref","first-page":"21513","DOI":"10.1016\/S0021-9258(20)80571-7","article-title":"Characterization of hypoxia-inducible factor 1 and regulation of DNA binding activity by hypoxia","volume":"268","author":"Wang","year":"1993","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.semcancer.2020.03.012_bib0120","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1073\/pnas.90.9.4304","article-title":"General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia","volume":"90","author":"Wang","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.012_bib0125","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1101\/gad.11.1.72","article-title":"Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells","volume":"11","author":"Tian","year":"1997","journal-title":"Genes Dev."},{"issue":"4","key":"10.1016\/j.semcancer.2020.03.012_bib0130","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1074\/jbc.274.4.2060","article-title":"Oxygen-regulated and transactivating domains in endothelial PAS protein 1: comparison with hypoxia-inducible factor-1alpha","volume":"274","author":"O\u2019Rourke","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.semcancer.2020.03.012_bib0135","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1182\/blood.V92.7.2260","article-title":"Induction of endothelial PAS domain protein-1 by hypoxia: characterization and comparison with hypoxia-inducible factor-1alpha","volume":"92","author":"Wiesener","year":"1998","journal-title":"Blood"},{"issue":"6733","key":"10.1016\/j.semcancer.2020.03.012_bib0140","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.semcancer.2020.03.012_bib0145","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/35017054","article-title":"Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein","volume":"2","author":"Ohh","year":"2000","journal-title":"Nat. Cell Biol."},{"issue":"5516","key":"10.1016\/j.semcancer.2020.03.012_bib0150","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1059796","article-title":"Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation","volume":"292","author":"Jaakkola","year":"2001","journal-title":"Science"},{"issue":"5516","key":"10.1016\/j.semcancer.2020.03.012_bib0155","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1126\/science.1059817","article-title":"HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.semcancer.2020.03.012_bib0160","doi-asserted-by":"crossref","first-page":"13459","DOI":"10.1073\/pnas.192342099","article-title":"Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor","volume":"99","author":"Ivan","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.012_bib0165","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0092-8674(01)00507-4","article-title":"C. Elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation","volume":"107","author":"Epstein","year":"2001","journal-title":"Cell"},{"issue":"42","key":"10.1016\/j.semcancer.2020.03.012_bib0170","doi-asserted-by":"crossref","first-page":"39792","DOI":"10.1074\/jbc.M206955200","article-title":"Sequence determinants in hypoxia-inducible factor-1alpha for hydroxylation by the prolyl hydroxylases PHD1, PHD2, and PHD3","volume":"277","author":"Huang","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"5545","key":"10.1016\/j.semcancer.2020.03.012_bib0175","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1126\/science.1066373","article-title":"A conserved family of prolyl-4-hydroxylases that modify HIF","volume":"294","author":"Bruick","year":"2001","journal-title":"Science"},{"issue":"5574","key":"10.1016\/j.semcancer.2020.03.012_bib0180","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1126\/science.1073440","article-title":"Structure of an HIF-1alpha -pVHL complex: hydroxyproline recognition in signaling","volume":"296","author":"Min","year":"2002","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.semcancer.2020.03.012_bib0185","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension","volume":"92","author":"Wang","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.semcancer.2020.03.012_bib0190","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3389\/fonc.2012.00035","article-title":"The roles of VHL-Dependent ubiquitination in signaling and Cancer","volume":"2","author":"Zhang","year":"2012","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.012_bib0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0016975","article-title":"Quantitative proteomics identifies the Myb-binding protein p160 as a novel target of the von Hippel-Lindau tumor suppressor","volume":"6","author":"Lai","year":"2011","journal-title":"PLoS One"},{"issue":"78","key":"10.1016\/j.semcancer.2020.03.012_bib0200","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2000444","article-title":"Oxygen-regulated beta(2)-adrenergic receptor hydroxylation by EGLN3 and ubiquitylation by pVHL","volume":"2","author":"Xie","year":"2009","journal-title":"Sci. Signal."},{"issue":"9","key":"10.1016\/j.semcancer.2020.03.012_bib0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0023936","article-title":"The von Hippel-Lindau tumor suppressor protein promotes c-Cbl-independent poly-ubiquitylation and degradation of the activated EGFR","volume":"6","author":"Zhou","year":"2011","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.semcancer.2020.03.012_bib0210","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.febslet.2007.02.059","article-title":"PKCzetaII is a target for degradation through the tumour suppressor protein pVHL","volume":"581","author":"Iturrioz","year":"2007","journal-title":"FEBS Lett."},{"issue":"5","key":"10.1016\/j.semcancer.2020.03.012_bib0215","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1073\/pnas.0436037100","article-title":"Von Hippel-Lindau protein binds hyperphosphorylated large subunit of RNA polymerase II through a proline hydroxylation motif and targets it for ubiquitination","volume":"100","author":"Kuznetsova","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"16","key":"10.1016\/j.semcancer.2020.03.012_bib0220","doi-asserted-by":"crossref","first-page":"4249","DOI":"10.1093\/emboj\/cdg410","article-title":"Identification of the RNA polymerase II subunit hsRPB7 as a novel target of the von Hippel-Lindau protein","volume":"22","author":"Na","year":"2003","journal-title":"EMBO J."},{"issue":"49","key":"10.1016\/j.semcancer.2020.03.012_bib0225","doi-asserted-by":"crossref","first-page":"42027","DOI":"10.1074\/jbc.M111.303222","article-title":"Regulation of cellular levels of Sprouty2 protein by prolyl hydroxylase domain and von Hippel-Lindau proteins","volume":"286","author":"Anderson","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"6399","key":"10.1016\/j.semcancer.2020.03.012_bib0230","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1126\/science.aap8411","article-title":"VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma","volume":"361","author":"Zhang","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2020.03.012_bib0235","article-title":"Genome-wide screening identifies SFMBT1 as an oncogenic driver in Cancer with VHL loss","author":"Liu","year":"2020","journal-title":"Mol. Cell"},{"issue":"7","key":"10.1016\/j.semcancer.2020.03.012_bib0240","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1097-2765(00)80096-9","article-title":"The von Hippel-Lindau tumor suppressor protein is required for proper assembly of an extracellular fibronectin matrix","volume":"1","author":"Ohh","year":"1998","journal-title":"Mol. Cell"},{"issue":"18","key":"10.1016\/j.semcancer.2020.03.012_bib0245","doi-asserted-by":"crossref","first-page":"13264","DOI":"10.1074\/jbc.M611648200","article-title":"Interaction of hydroxylated collagen IV with the von hippel-lindau tumor suppressor","volume":"282","author":"Grosfeld","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.012_bib0250","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.molcel.2007.09.010","article-title":"pVHL acts as an adaptor to promote the inhibitory phosphorylation of the NF-kappaB agonist Card9 by CK2","volume":"28","author":"Yang","year":"2007","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.012_bib0255","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/path.4219","article-title":"Regulation of E2F1 by the von Hippel-Lindau tumour suppressor protein predicts survival in renal cell cancer patients","volume":"231","author":"Mans","year":"2013","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.012_bib0260","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1042\/BJ20130793","article-title":"pVHL acts as a downstream target of E2F1 to suppress E2F1 activity","volume":"457","author":"Ji","year":"2014","journal-title":"Biochem. J."},{"issue":"6302","key":"10.1016\/j.semcancer.2020.03.012_bib0265","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1126\/science.aad5755","article-title":"pVHL suppresses kinase activity of Akt in a proline-hydroxylation-dependent manner","volume":"353","author":"Guo","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2020.03.012_bib0270","article-title":"TBK1 is a synthetic lethal target in Cancer with VHL loss","author":"Hu","year":"2019","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.012_bib0275","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/ncb1699","article-title":"VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400","volume":"10","author":"Young","year":"2008","journal-title":"Nat. Cell Biol."},{"issue":"19","key":"10.1016\/j.semcancer.2020.03.012_bib0280","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1128\/MCB.01618-09","article-title":"Renal oxygenation suppresses VHL loss-induced senescence that is caused by increased sensitivity to oxidative stress","volume":"30","author":"Welford","year":"2010","journal-title":"Mol. Cell. Biol."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.012_bib0285","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1073\/pnas.0509459103","article-title":"Mouse model for noninvasive imaging of HIF prolyl hydroxylase activity: assessment of an oral agent that stimulates erythropoietin production","volume":"103","author":"Safran","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.012_bib0290","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0022-5347(05)67889-5","article-title":"Systemic therapy for renal cell carcinoma","volume":"163","author":"Motzer","year":"2000","journal-title":"J. Urol."},{"issue":"7","key":"10.1016\/j.semcancer.2020.03.012_bib0295","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1158\/0008-5472.CAN-15-1859","article-title":"Formation of renal cysts and tumors in Vhl\/Trp53-Deficient mice requires HIF1alpha and HIF2alpha","volume":"76","author":"Schonenberger","year":"2016","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.012_bib0300","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1535-6108(02)00048-X","article-title":"Two HIFs may be better than one","volume":"1","author":"Seagroves","year":"2002","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.012_bib0305","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1128\/MCB.23.1.359-369.2003","article-title":"Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia","volume":"23","author":"Goda","year":"2003","journal-title":"Mol. Cell. Biol."},{"issue":"11","key":"10.1016\/j.semcancer.2020.03.012_bib0310","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1158\/0008-5472.CAN-09-0146","article-title":"Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney","volume":"69","author":"Beroukhim","year":"2009","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.012_bib0315","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1158\/2159-8290.CD-11-0098","article-title":"Genetic and functional studies implicate HIF1alpha as a 14q kidney cancer suppressor gene","volume":"1","author":"Shen","year":"2011","journal-title":"Cancer Discov."},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.012_bib0320","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S1535-6108(02)00044-2","article-title":"The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma","volume":"1","author":"Maranchie","year":"2002","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.012_bib0325","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ccr.2008.10.016","article-title":"HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma","volume":"14","author":"Gordan","year":"2008","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.012_bib0330","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1371\/journal.pbio.0000083","article-title":"Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth","volume":"1","author":"Kondo","year":"2003","journal-title":"PLoS Biol."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.012_bib0335","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.gde.2006.12.006","article-title":"Hypoxia-inducible factors: central regulators of the tumor phenotype","volume":"17","author":"Gordan","year":"2007","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"2","key":"10.1016\/j.semcancer.2020.03.012_bib0340","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ccr.2007.07.006","article-title":"HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation","volume":"12","author":"Gordan","year":"2007","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.semcancer.2020.03.012_bib0345","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ccr.2007.02.006","article-title":"HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity","volume":"11","author":"Gordan","year":"2007","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.semcancer.2020.03.012_bib0350","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1172\/JCI73665","article-title":"Pharmacological HIF2alpha inhibition improves VHL disease-associated phenotypes in zebrafish model","volume":"125","author":"Metelo","year":"2015","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.012_bib0355","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.molcel.2008.12.004","article-title":"Small-molecule inhibitors of HIF-2a translation link its 5\u2019UTR iron-responsive element to oxygen sensing","volume":"32","author":"Zimmer","year":"2008","journal-title":"Mol. Cell"},{"issue":"4","key":"10.1016\/j.semcancer.2020.03.012_bib0360","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nchembio.1185","article-title":"Allosteric inhibition of hypoxia inducible factor-2 with small molecules","volume":"9","author":"Scheuermann","year":"2013","journal-title":"Nat. Chem. Biol."},{"issue":"7627","key":"10.1016\/j.semcancer.2020.03.012_bib0365","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature19796","article-title":"Targeting renal cell carcinoma with a HIF-2 antagonist","volume":"539","author":"Chen","year":"2016","journal-title":"Nature"},{"issue":"7627","key":"10.1016\/j.semcancer.2020.03.012_bib0370","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature19795","article-title":"On-target efficacy of a HIF-2alpha antagonist in preclinical kidney cancer models","volume":"539","author":"Cho","year":"2016","journal-title":"Nature"},{"issue":"18","key":"10.1016\/j.semcancer.2020.03.012_bib0375","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.1158\/0008-5472.CAN-16-0473","article-title":"A small-molecule antagonist of HIF2alpha is efficacious in preclinical models of renal cell carcinoma","volume":"76","author":"Wallace","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2020.03.012_bib0380","article-title":"Phase I dose-escalation trial of PT2385, a first-in-Class hypoxia-inducible Factor-2alpha antagonist in patients with previously treated advanced clear cell renal cell carcinoma","author":"Courtney","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.semcancer.2020.03.012_bib0385","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1200\/JCO.2017.77.5254","article-title":"HIF2 inhibitor joins the kidney Cancer armamentarium","volume":"36","author":"Kaelin","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"6 Pt 1","key":"10.1016\/j.semcancer.2020.03.012_bib0390","doi-asserted-by":"crossref","first-page":"C1362","DOI":"10.1152\/ajpcell.1995.268.6.C1362","article-title":"Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents","volume":"268","author":"Gleadle","year":"1995","journal-title":"Am. J. Physiol."},{"issue":"8","key":"10.1016\/j.semcancer.2020.03.012_bib0395","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20081901","article-title":"Targeting tyrosine kinases in renal cell carcinoma: \u201cNew bullets against old guys\u201d","volume":"20","author":"Alonso-Gordoa","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.semcancer.2020.03.012_bib0400","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/nrurol.2013.26","article-title":"Hijacking the vasculature in ccRCC--co-option, remodelling and angiogenesis","volume":"10","author":"Qian","year":"2013","journal-title":"Nat. Rev. Urol."},{"issue":"43","key":"10.1016\/j.semcancer.2020.03.012_bib0405","doi-asserted-by":"crossref","first-page":"16484","DOI":"10.1073\/pnas.0806574105","article-title":"Kinase requirements in human cells: III. Altered kinase requirements in VHL-\/- cancer cells detected in a pilot synthetic lethal screen","volume":"105","author":"Bommi-Reddy","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"8","key":"10.1016\/j.semcancer.2020.03.012_bib0410","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1093\/annonc\/mdu184","article-title":"A phase I study of cabozantinib (XL184) in patients with renal cell cancer","volume":"25","author":"Choueiri","year":"2014","journal-title":"Ann. Oncol."},{"issue":"3215","key":"10.1016\/j.semcancer.2020.03.012_bib0415","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1126\/science.124.3215.269","article-title":"On respiratory impairment in cancer cells","volume":"124","author":"Warburg","year":"1956","journal-title":"Science"},{"issue":"38","key":"10.1016\/j.semcancer.2020.03.012_bib0420","doi-asserted-by":"crossref","first-page":"23757","DOI":"10.1016\/S0021-9258(17)31580-6","article-title":"Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1","volume":"269","author":"Semenza","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"36","key":"10.1016\/j.semcancer.2020.03.012_bib0425","doi-asserted-by":"crossref","first-page":"21021","DOI":"10.1074\/jbc.270.36.21021","article-title":"Hypoxic regulation of lactate dehydrogenase A. Interaction between hypoxia-inducible factor 1 and cAMP response elements","volume":"270","author":"Firth","year":"1995","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.012_bib0430","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.cmet.2006.02.002","article-title":"HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia","volume":"3","author":"Kim","year":"2006","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.012_bib0435","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cmet.2006.01.012","article-title":"HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption","volume":"3","author":"Papandreou","year":"2006","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.012_bib0440","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cmet.2006.02.007","article-title":"Coming up for air: HIF-1 and mitochondrial oxygen consumption","volume":"3","author":"Simon","year":"2006","journal-title":"Cell Metab."},{"key":"10.1016\/j.semcancer.2020.03.012_bib0445","doi-asserted-by":"crossref","first-page":"e1585","DOI":"10.1038\/cddis.2014.545","article-title":"Primary clear cell renal carcinoma cells display minimal mitochondrial respiratory capacity resulting in pronounced sensitivity to glycolytic inhibition by 3-Bromopyruvate","volume":"6","author":"Nilsson","year":"2015","journal-title":"Cell Death Dis."},{"issue":"7381","key":"10.1016\/j.semcancer.2020.03.012_bib0450","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature10602","article-title":"Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia","volume":"481","author":"Metallo","year":"2011","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.012_bib0455","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.cmet.2013.02.002","article-title":"In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation","volume":"17","author":"Gameiro","year":"2013","journal-title":"Cell Metab."},{"issue":"5","key":"10.1016\/j.semcancer.2020.03.012_bib0460","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1172\/JCI87800","article-title":"Glutaminase and poly(ADP-ribose) polymerase inhibitors suppress pyrimidine synthesis and VHL-deficient renal cancers","volume":"127","author":"Okazaki","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"9637","key":"10.1016\/j.semcancer.2020.03.012_bib0465","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.semcancer.2020.03.012_bib0470","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1101\/gad.1256804","article-title":"Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1\/TSC2 tumor suppressor complex","volume":"18","author":"Brugarolas","year":"2004","journal-title":"Genes Dev."},{"issue":"9","key":"10.1016\/j.semcancer.2020.03.012_bib0475","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1158\/1541-7786.MCR-11-0302","article-title":"Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma","volume":"9","author":"Kucejova","year":"2011","journal-title":"Mol. Cancer Res."},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.012_bib0480","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1158\/2159-8290.CD-14-1507","article-title":"HIF2alpha-dependent lipid storage promotes endoplasmic reticulum homeostasis in clear-cell renal cell carcinoma","volume":"5","author":"Qiu","year":"2015","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.012_bib0485","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/s41467-017-01965-8","article-title":"HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism","volume":"8","author":"Du","year":"2017","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.semcancer.2020.03.012_bib0490","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1158\/2159-8290.CD-13-0696","article-title":"L-2-Hydroxyglutarate: an epigenetic modifier and putative oncometabolite in renal cancer","volume":"4","author":"Shim","year":"2014","journal-title":"Cancer Discov."},{"issue":"7274","key":"10.1016\/j.semcancer.2020.03.012_bib0495","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.012_bib0500","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.semcancer.2020.03.012_bib0505","doi-asserted-by":"crossref","first-page":"6433","DOI":"10.1158\/1078-0432.CCR-18-1727","article-title":"Biochemical and epigenetic insights into L-2-Hydroxyglutarate, a potential therapeutic target in renal Cancer","volume":"24","author":"Shelar","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2020.03.012_bib0510","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1172\/JCI98747","article-title":"Ascorbic acid-induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma","volume":"130","author":"Shenoy","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.012_bib0515","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ccr.2008.06.004","article-title":"A molecule targeting VHL-deficient renal cell carcinoma that induces autophagy","volume":"14","author":"Turcotte","year":"2008","journal-title":"Cancer Cell"},{"issue":"94","key":"10.1016\/j.semcancer.2020.03.012_bib0520","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002394","article-title":"Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality","volume":"3","author":"Chan","year":"2011","journal-title":"Sci. Transl. Med."},{"issue":"601","key":"10.1016\/j.semcancer.2020.03.012_bib0525","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aay0482","article-title":"HIF-independent synthetic lethality between CDK4\/6 inhibition and VHL loss across species","volume":"12","author":"Nicholson","year":"2019","journal-title":"Sci. Signal."},{"key":"10.1016\/j.semcancer.2020.03.012_bib0530","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1089\/crispr.2019.0018","article-title":"VHL synthetic lethality signatures uncovered by genotype-specific CRISPR-Cas9 screens","volume":"2","author":"Sun","year":"2019","journal-title":"CRISPR J"},{"issue":"8","key":"10.1016\/j.semcancer.2020.03.012_bib0535","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1186\/s13059-014-0433-z","article-title":"Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution","volume":"15","author":"Fisher","year":"2014","journal-title":"Genome Biol."},{"issue":"3","key":"10.1016\/j.semcancer.2020.03.012_bib0540","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ng.2891","article-title":"Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing","volume":"46","author":"Gerlinger","year":"2014","journal-title":"Nat. Genet."},{"issue":"10","key":"10.1016\/j.semcancer.2020.03.012_bib0545","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"7331","key":"10.1016\/j.semcancer.2020.03.012_bib0550","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature09639","article-title":"Exome sequencing identifies frequent mutation of the SWI\/SNF complex gene PBRM1 in renal carcinoma","volume":"469","author":"Varela","year":"2011","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.semcancer.2020.03.012_bib0555","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1016\/j.celrep.2017.02.074","article-title":"The SWI\/SNF protein PBRM1 restrains VHL-Loss-Driven clear cell renal cell carcinoma","volume":"18","author":"Nargund","year":"2017","journal-title":"Cell Rep."},{"issue":"5","key":"10.1016\/j.semcancer.2020.03.012_bib0560","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1073\/pnas.1619726114","article-title":"Inactivation of the PBRM1 tumor suppressor gene amplifies the HIF-response in VHL-\/- clear cell renal carcinoma","volume":"114","author":"Gao","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.semcancer.2020.03.012_bib0565","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Pena-Llopis","year":"2012","journal-title":"Nat. Genet."},{"issue":"7279","key":"10.1016\/j.semcancer.2020.03.012_bib0570","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/nature08672","article-title":"Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes","volume":"463","author":"Dalgliesh","year":"2010","journal-title":"Nature"},{"issue":"52","key":"10.1016\/j.semcancer.2020.03.012_bib0575","doi-asserted-by":"crossref","first-page":"36542","DOI":"10.1074\/jbc.M804578200","article-title":"The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF","volume":"283","author":"Beyer","year":"2008","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.012_bib0580","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1128\/MCB.00444-09","article-title":"Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth","volume":"30","author":"Krieg","year":"2010","journal-title":"Mol. Cell. Biol."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.012_bib0585","doi-asserted-by":"crossref","first-page":"43","DOI":"10.14348\/molcells.2014.2250","article-title":"HIF-1-dependent induction of Jumonji domain-containing protein (JMJD) 3 under hypoxic conditions","volume":"37","author":"Lee","year":"2014","journal-title":"Mol. Cells"},{"issue":"4","key":"10.1016\/j.semcancer.2020.03.012_bib0590","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.bbrc.2008.05.150","article-title":"Hypoxia upregulates the histone demethylase JMJD1A via HIF-1","volume":"372","author":"Wellmann","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/j.semcancer.2020.03.012_bib0595","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1073\/pnas.0810067106","article-title":"Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis","volume":"106","author":"Xia","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"16","key":"10.1016\/j.semcancer.2020.03.012_bib0600","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.1158\/0008-5472.CAN-10-0413","article-title":"The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth","volume":"70","author":"Yang","year":"2010","journal-title":"Cancer Res."},{"issue":"398","key":"10.1016\/j.semcancer.2020.03.012_bib0605","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal5272","article-title":"HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase","volume":"9","author":"Chakraborty","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.semcancer.2020.03.012_bib0610","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1146\/annurev-immunol-032414-112049","article-title":"Coinhibitory pathways in immunotherapy for cancer","volume":"34","author":"Baumeister","year":"2016","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.012_bib0615","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2018.10.010","article-title":"Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: current paradigms, use of immunotherapy, and future directions","volume":"75","author":"Lalani","year":"2019","journal-title":"Eur. Urol."},{"issue":"12","key":"10.1016\/j.semcancer.2020.03.012_bib0620","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6377","key":"10.1016\/j.semcancer.2020.03.012_bib0625","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"Miao","year":"2018","journal-title":"Science"},{"issue":"8","key":"10.1016\/j.semcancer.2020.03.012_bib0630","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/s41591-018-0116-5","article-title":"Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses","volume":"24","author":"Canadas","year":"2018","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.semcancer.2020.03.012_bib0635","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1172\/JCI121476","article-title":"Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma","volume":"128","author":"Smith","year":"2018","journal-title":"J. Clin. Invest."},{"issue":"16","key":"10.1016\/j.semcancer.2020.03.012_bib0640","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.121522","article-title":"Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma","volume":"3","author":"Panda","year":"2018","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.semcancer.2020.03.012_bib0645","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12943-016-0565-8","article-title":"Choosing the right cell line for renal cell cancer research","volume":"15","author":"Brodaczewska","year":"2016","journal-title":"Mol. Cancer"},{"issue":"8","key":"10.1016\/j.semcancer.2020.03.012_bib0650","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/bjc.2016.263","article-title":"MEK inhibition abrogates sunitinib resistance in a renal cell carcinoma patient-derived xenograft model","volume":"115","author":"Diaz-Montero","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"13","key":"10.1016\/j.semcancer.2020.03.012_bib0655","doi-asserted-by":"crossref","first-page":"15507","DOI":"10.18632\/oncotarget.6266","article-title":"Isolation and characterization of renal cancer stem cells from patient-derived xenografts","volume":"7","author":"Hasmim","year":"2016","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.semcancer.2020.03.012_bib0660","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.celrep.2016.04.015","article-title":"Resistance to antiangiogenic therapies by metabolic symbiosis in renal cell carcinoma PDX models and patients","volume":"15","author":"Jimenez-Valerio","year":"2016","journal-title":"Cell Rep."},{"issue":"Suppl 2","key":"10.1016\/j.semcancer.2020.03.012_bib0665","doi-asserted-by":"crossref","first-page":"S156","DOI":"10.21037\/tau.2018.11.04","article-title":"Patient-derived xenograft models to optimize kidney cancer therapies","volume":"8","author":"Patel","year":"2019","journal-title":"Transl. Androl. Urol."},{"issue":"9","key":"10.1016\/j.semcancer.2020.03.012_bib0670","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/2159-8290.CD-17-1246","article-title":"An empirical approach leveraging tumorgrafts to dissect the tumor microenvironment in renal cell carcinoma identifies missing link to prognostic inflammatory factors","volume":"8","author":"Wang","year":"2018","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.semcancer.2020.03.012_bib0675","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1158\/0008-5472.CAN-05-3241","article-title":"Renal cyst development in mice with conditional inactivation of the von Hippel-Lindau tumor suppressor","volume":"66","author":"Rankin","year":"2006","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.semcancer.2020.03.012_bib0680","first-page":"3879","article-title":"Von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis","volume":"117","author":"Hickey","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.semcancer.2020.03.012_bib0685","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1158\/2159-8290.CD-17-0292","article-title":"Modeling renal cell carcinoma in mice: Bap1 and Pbrm1 inactivation drive tumor grade","volume":"7","author":"Gu","year":"2017","journal-title":"Cancer Discov."},{"issue":"46","key":"10.1016\/j.semcancer.2020.03.012_bib0690","doi-asserted-by":"crossref","first-page":"16538","DOI":"10.1073\/pnas.1414789111","article-title":"Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis","volume":"111","author":"Wang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.semcancer.2020.03.012_bib0695","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/nm.4343","article-title":"Combined mutation in Vhl, Trp53 and Rb1 causes clear cell renal cell carcinoma in mice","volume":"23","author":"Harlander","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2020.03.012_bib0700","doi-asserted-by":"crossref","first-page":"15770","DOI":"10.1038\/ncomms15770","article-title":"MYC activation cooperates with Vhl and Ink4a\/Arf loss to induce clear cell renal cell carcinoma","volume":"8","author":"Bailey","year":"2017","journal-title":"Nat. Commun."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X2030078X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X2030078X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:41:08Z","timestamp":1760917268000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X2030078X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":140,"alternative-id":["S1044579X2030078X"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2020.03.012","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Coalescing lessons from oxygen sensing, tumor metabolism, and epigenetics to target VHL loss in kidney cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2020.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}